106 related articles for article (PubMed ID: 31694041)
1. Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance.
Park J; Yoo S; Cho MC; Jeong CW; Ku JH; Kwak C; Kim HH; Jeong H
Urol Int; 2020; 104(3-4):199-204. PubMed ID: 31694041
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical outcomes between upgraded pathologic Gleason score 3 + 4 and non-upgraded 3 + 4 prostate cancer among patients who are candidates for active surveillance.
Jo JK; Hong SK; Byun SS; Lee SE; Oh JJ
World J Urol; 2015 Nov; 33(11):1729-34. PubMed ID: 25809876
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of the Disparity Between Biopsy and Pathologic Gleason Score After Radical Prostatectomy in Clinical Candidates for Active Surveillance According to the Royal Marsden Criteria.
Jo JK; Hong SK; Byun SS; Lee SE; Lee S; Oh JJ
Clin Genitourin Cancer; 2016 Aug; 14(4):e329-33. PubMed ID: 26935997
[TBL] [Abstract][Full Text] [Related]
4. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
5. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
6. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
McGinley KF; Sun X; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
Int J Urol; 2017 Aug; 24(8):611-617. PubMed ID: 28589550
[TBL] [Abstract][Full Text] [Related]
8. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
9. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
[TBL] [Abstract][Full Text] [Related]
10. Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
Wong LM; Tang V; Peters J; Costello A; Corcoran N
BJU Int; 2016 Apr; 117 Suppl 4():82-7. PubMed ID: 27094971
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
12. Favorable Gleason 3 + 4 Prostate Cancer Shows Comparable Outcomes With Gleason 3 + 3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance.
Lee H; Lee IJ; Byun SS; Lee SE; Hong SK
Clin Genitourin Cancer; 2017 Dec; 15(6):e1117-e1122. PubMed ID: 28843377
[TBL] [Abstract][Full Text] [Related]
13. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.
Tosoian JJ; JohnBull E; Trock BJ; Landis P; Epstein JI; Partin AW; Walsh PC; Carter HB
J Urol; 2013 Oct; 190(4):1218-22. PubMed ID: 23643603
[TBL] [Abstract][Full Text] [Related]
14. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.
Ellis CL; Partin AW; Han M; Epstein JI
J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307
[TBL] [Abstract][Full Text] [Related]
15. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
16. Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy.
Brimo F; Xu B; Scarlata E; Bégin LR; Spatz A; Salomon L; Zakaria AS; Ploussard G; Bladou F; Kassouf W; Tanguay S; Chevalier S; Ye H; Aprikian A
Hum Pathol; 2014 Oct; 45(10):2006-13. PubMed ID: 25152453
[TBL] [Abstract][Full Text] [Related]
17. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
[TBL] [Abstract][Full Text] [Related]
18. Is active surveillance a safe alternative in the management of localized prostate cancer? Pathological features of radical prostatectomy specimens in potential candidates for active surveillance.
Norman Z; Militza P; Andres F; Daniela F; Alejandro M; Catherine S; Juan F
Int Braz J Urol; 2014; 40(2):154-9. PubMed ID: 24856482
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.
Diniz CP; Landis P; Carter HB; Epstein JI; Mamawala M
J Urol; 2017 Sep; 198(3):608-613. PubMed ID: 28347771
[TBL] [Abstract][Full Text] [Related]
20. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
